2 High-Risk, High-Reward Stocks for Contrarian Investors
Feeling adventurous?
Bluebird Bio(BLUE)
Nasdaq Global Select
BLUE
$3.27
-$0.08
-2.4%
Price as of May 20, 2022, 4:00 p.m. ET
View Interactive BLUE Charts
Bluebird Bio is a development-stage biotechnology company focused on gene therapy, gene editing, and cancer immunotherapy.
Interactive Chart
Compare BLUE Stock to Peers
| Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
|---|---|---|---|---|
|
BLUE
Bluebird Bio
|
$3.27 | $234M | -82.4% | -93.4% |
|
NVTA |
$3.63 | $832M | -86.1% | -58.0% |
|
EDIT |
$11.02 | $756M | -67.0% | -37.3% |
|
CMPS |
$8.36 | $355M | -76.1% | |
|
KOD |
$6.96 | $359M | -91.7% |
News & Analysis: Bluebird Bio
The Fool has written over 200 articles on Bluebird Bio.
Where Will Bluebird Bio Be in 1 Year?
It's going to be an interesting next 12 months for the biotech.
Is Bluebird Bio a Buy?
The expected upcoming catalysts might not be all that the company needs.
Why Bluebird Bio Stock Is Sinking This Week
The unexpected departure of its CFO and an ominous note of caution rattled investors.
Why Bluebird Bio Stock Is Sinking Today
The biotech's financial position has some investors worried.
2 Dirt Cheap Biotechs to Buy If You're a Contrarian
Today's losers are selling for peanuts, and they just might become tomorrow's winners.
2 Money-Burning Biotech Stocks to Avoid
These companies have taken a beating, and there's no relief on the horizon.
2 Biotech Stocks That Could Make You Richer
These two companies are down, but they aren't yet out.
Why Bluebird Bio Stock Is Sinking This Week
The biotech's latest corporate update wasn't well received by investors this week.
Why Bluebird Bio Stock Is Plunging Today
The FDA placed a partial clinical hold on Bluebird's clinical studies of lovo-cel.
